
ChemPass is a Hungary-based drug discovery company specializing in AI-assisted lead discovery and medicinal chemistry problem solving. Their proprietary AI platform, including the SynSpace design platform, enables rapid and synthetically reliable design of chemical libraries and lead optimization ideation tasks such as scaffold hopping and retrosynthesis. ChemPass offers services like universal fragment library design, virtual chemoproteomics, and giga-scale virtual screening, targeting biotech and pharmaceutical companies to accelerate drug candidate identification with reduced timelines and costs. Their technology is validated by collaborations and case studies, positioning them as an innovative player in AI-driven drug discovery with a strong synthetic chemistry foundation and expert team.

ChemPass is a Hungary-based drug discovery company specializing in AI-assisted lead discovery and medicinal chemistry problem solving. Their proprietary AI platform, including the SynSpace design platform, enables rapid and synthetically reliable design of chemical libraries and lead optimization ideation tasks such as scaffold hopping and retrosynthesis. ChemPass offers services like universal fragment library design, virtual chemoproteomics, and giga-scale virtual screening, targeting biotech and pharmaceutical companies to accelerate drug candidate identification with reduced timelines and costs. Their technology is validated by collaborations and case studies, positioning them as an innovative player in AI-driven drug discovery with a strong synthetic chemistry foundation and expert team.
Founded: 2016
Headquarters: Budapest, Hungary
Focus: AI-assisted small-molecule drug discovery and medicinal chemistry
Flagship platform: SynSpace (synthetically reliable chemical-space design)
Known investor: Hiventures (lead investor on reported Seed round)
Small-molecule drug discovery and medicinal chemistry ideation
2016
Biotechnology
Seed round reported on Aug 29, 2018 with Hiventures named as lead investor.
“Hiventures participation on Seed round indicates institutional early-stage backing”